These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 24116714)

  • 1. Visually interpretable models of kinase selectivity related features derived from field-based proteochemometrics.
    Subramanian V; Prusis P; Pietilä LO; Xhaard H; Wohlfahrt G
    J Chem Inf Model; 2013 Nov; 53(11):3021-30. PubMed ID: 24116714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Profile-QSAR: a novel meta-QSAR method that combines activities across the kinase family to accurately predict affinity, selectivity, and cellular activity.
    Martin E; Mukherjee P; Sullivan D; Jansen J
    J Chem Inf Model; 2011 Aug; 51(8):1942-56. PubMed ID: 21667971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinase selectivity potential for inhibitors targeting the ATP binding site: a network analysis.
    Huang D; Zhou T; Lafleur K; Nevado C; Caflisch A
    Bioinformatics; 2010 Jan; 26(2):198-204. PubMed ID: 19942586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. kinDOCK: a tool for comparative docking of protein kinase ligands.
    Martin L; Catherinot V; Labesse G
    Nucleic Acids Res; 2006 Jul; 34(Web Server issue):W325-9. PubMed ID: 16845019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrating ligand-based and protein-centric virtual screening of kinase inhibitors using ensembles of multiple protein kinase genes and conformations.
    Dixit A; Verkhivker GM
    J Chem Inf Model; 2012 Oct; 52(10):2501-15. PubMed ID: 22992037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KLIFS: a knowledge-based structural database to navigate kinase-ligand interaction space.
    van Linden OP; Kooistra AJ; Leurs R; de Esch IJ; de Graaf C
    J Med Chem; 2014 Jan; 57(2):249-77. PubMed ID: 23941661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases.
    Comess KM; Sun C; Abad-Zapatero C; Goedken ER; Gum RJ; Borhani DW; Argiriadi M; Groebe DR; Jia Y; Clampit JE; Haasch DL; Smith HT; Wang S; Song D; Coen ML; Cloutier TE; Tang H; Cheng X; Quinn C; Liu B; Xin Z; Liu G; Fry EH; Stoll V; Ng TI; Banach D; Marcotte D; Burns DJ; Calderwood DJ; Hajduk PJ
    ACS Chem Biol; 2011 Mar; 6(3):234-44. PubMed ID: 21090814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Classification and comparison of ligand-binding sites derived from grid-mapped knowledge-based potentials.
    Hoppe C; Steinbeck C; Wohlfahrt G
    J Mol Graph Model; 2006 Mar; 24(5):328-40. PubMed ID: 16260161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-based and multiple potential three-dimensional quantitative structure-activity relationship (SB-MP-3D-QSAR) for inhibitor design.
    Du QS; Gao J; Wei YT; Du LQ; Wang SQ; Huang RB
    J Chem Inf Model; 2012 Apr; 52(4):996-1004. PubMed ID: 22480344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved approach for proteochemometrics modeling: application to organic compound--amine G protein-coupled receptor interactions.
    Lapinsh M; Prusis P; Uhlén S; Wikberg JE
    Bioinformatics; 2005 Dec; 21(23):4289-96. PubMed ID: 16204343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel kinase inhibitors by reshuffling ligand functionalities across the human kinome.
    Vidović D; Muskal SM; Schürer SC
    J Chem Inf Model; 2012 Dec; 52(12):3107-15. PubMed ID: 23121521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural approaches to obtain kinase selectivity.
    Norman RA; Toader D; Ferguson AD
    Trends Pharmacol Sci; 2012 May; 33(5):273-8. PubMed ID: 22503441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modeling the binding affinity of p38α MAP kinase inhibitors by partial least squares regression.
    Basant N; Durante C; Cocchi M; Menziani MC
    Chem Biol Drug Des; 2012 Sep; 80(3):455-70. PubMed ID: 22642504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural interaction fingerprint (SIFt): a novel method for analyzing three-dimensional protein-ligand binding interactions.
    Deng Z; Chuaqui C; Singh J
    J Med Chem; 2004 Jan; 47(2):337-44. PubMed ID: 14711306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pocketome of human kinases: prioritizing the ATP binding sites of (yet) untapped protein kinases for drug discovery.
    Volkamer A; Eid S; Turk S; Jaeger S; Rippmann F; Fulle S
    J Chem Inf Model; 2015 Mar; 55(3):538-49. PubMed ID: 25557645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonlinear scoring functions for similarity-based ligand docking and binding affinity prediction.
    Brylinski M
    J Chem Inf Model; 2013 Nov; 53(11):3097-112. PubMed ID: 24171431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toward a pharmacophore for kinase frequent hitters.
    Aronov AM; Murcko MA
    J Med Chem; 2004 Nov; 47(23):5616-9. PubMed ID: 15509160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small kinase assay panels can provide a measure of selectivity.
    Brandt P; Jensen AJ; Nilsson J
    Bioorg Med Chem Lett; 2009 Oct; 19(20):5861-3. PubMed ID: 19748779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analyzing Kinase Similarity in Small Molecule and Protein Structural Space to Explore the Limits of Multi-Target Screening.
    Schmidt D; Scharf MM; Sydow D; Aßmann E; Martí-Solano M; Keul M; Volkamer A; Kolb P
    Molecules; 2021 Jan; 26(3):. PubMed ID: 33530327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors.
    Laufer SA; Domeyer DM; Scior TR; Albrecht W; Hauser DR
    J Med Chem; 2005 Feb; 48(3):710-22. PubMed ID: 15689155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.